[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,023,405
  • Shares Outstanding, K 184,956
  • Annual Sales, $ 1,029 M
  • Annual Income, $ -296,800 K
  • EBIT $ -251 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.29
  • Price/Sales 5.08
  • Price/Cash Flow N/A
  • Price/Book 5.40

Options Overview Details

View History
  • Implied Volatility 85.98% (+3.17%)
  • Historical Volatility 86.03%
  • IV Percentile 93%
  • IV Rank 55.75%
  • IV High 119.66% on 03/19/26
  • IV Low 43.54% on 11/14/25
  • Expected Move (DTE 17) 4.32 (16.93%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 2,388
  • Volume Avg (30-Day) 1,863
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 18,500
  • Open Int (30-Day) 20,896
  • Expected Range 21.19 to 29.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.05
  • Number of Estimates 7
  • High Estimate $0.12
  • Low Estimate $-0.09
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) +114.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.57 +8.23%
on 05/04/26
30.41 -16.11%
on 05/05/26
+1.92 (+8.14%)
since 05/01/26
3-Month
16.70 +52.75%
on 03/30/26
30.41 -16.11%
on 05/05/26
+6.51 (+34.26%)
since 02/27/26
52-Week
16.24 +57.08%
on 02/04/26
45.30 -43.68%
on 07/23/25
-3.44 (-11.88%)
since 05/30/25

Most Recent Stories

More News
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients  Responses observed at higher dose levels of LB2102 with an ORR of...

LEGN : 25.51 (-6.08%)
Legend Biotech Announces Presentations at ASCO 2026

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic...

LEGN : 25.51 (-6.08%)
Legend Biotech Q1 Earnings Call Highlights

Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment...

LEGN : 25.51 (-6.08%)
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 million CARVYKTI ® now available across 18 global markets,...

LEGN : 25.51 (-6.08%)
Legend Biotech's Manufacturing Expansion Could Be Masking a Demand Problem for CARVYKTI

Barchart Research What to Expect from LEGN Earnings LEGN Generated May 11, 2026 Current Price $25.58 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 3.20% Legend Biotech's Manufacturing...

LEGN : 25.51 (-6.08%)
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished...

LEGN : 25.51 (-6.08%)
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...

LEGN : 25.51 (-6.08%)
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of...

LEGN : 25.51 (-6.08%)
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...

LEGN : 25.51 (-6.08%)
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan....

LEGN : 25.51 (-6.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 28.93
2nd Resistance Point 27.96
1st Resistance Point 26.74
Last Price 25.51
1st Support Level 24.55
2nd Support Level 23.58
3rd Support Level 22.36

See More

52-Week High 45.30
Fibonacci 61.8% 34.20
Fibonacci 50% 30.77
Fibonacci 38.2% 27.34
Last Price 25.51
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.